Suven Pharmaceutical News

We are pleased to inform you that the United States Food & Drug Administration (US FDA) has completed the surveillance unspection of Casper Pharma Private Limited in Hyderabad (WOS of our Company) The Inspection took place frol July 8, 2024 to July 12, 2024. Following the inspection, we have been issed a Form 483 with two observations, which are procedural in nature.

Copy of news paper advertisiment

Suven Pharmaceuticals Limited has acquired 51% of the share Capital on a fully diluted basis (i.e., 67.5% of the present equity share capital) of Sapala Organics Private Limited

Book Closure

Appointment of Walker Chandiok & Co LLP as Statutory auditors of the Company w.e.f 07 July 2024 subject to approval of members.

With reference to the above subject, we wish to inform you that the Board of Directors of the company, at its meeting held today i.e. July 12, 2024, approved the following along with other business matters.1. Appointment of Statutory Auditors: 2. e-Annual General Meeting (AGM):a) Approved the Notice and Agenda for the 6th Annual General Meeting (AGM) of the Members of the Company scheduled to be held on Friday, the 09th day of August, 2024 at 4.30 p.m. through Video-Conferencing ('VC') or Other Audio Visual Means ('OAVM')b) Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, the Register of Member and Share Transfer Books of the Company will remain closed from August 07, 2024 to August 09, 2024 (both days inclusive) for the purpose of 6th Annual General Meeting of the Company.We request you to take this document on your records. The Board Meeting commenced at 02:30 p.m. and concluded at 03.45 p.m.

Intimation of closure of Trading Window

Transcript of the conference call for acquisition of a majority stake in Sapala Organics

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for DB Trustee (Hong Kong) Ltd

Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and with reference to our conference call intimation dated June 13, 2024, the audio recording of the conference call for acquisition of a majority stake in Sapala Organics held on Wednesday, June 19, 2024, has beenuploaded on the Company''s website

The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for CSCGlobal Capital Markets Singapore Pte Ltd

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 18, 2024 for Berhyanda Ltd & Berhyanda Midco Ltd

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 18, 2024 for Berhyanda Ltd & Berhyanda Midco Ltd

Update on amalgamation of Casper Pharma Pvt Ltd (WOS) into and with Suven Pharmaceuticals Limited is attached.

Equity indices hit record levels on Thursday after lower-than-expected inflation hints at RBI interest rate cut. L&T Finance, Ambuja Cement, Vodafone Idea, Puravankara, NITCO, Wipro, Nalco, Suven Pharma, and MosChip Technology make significant moves. Adani Group-owned Ambuja Cement acquires Penna Cement at Rs 10,422 crore. Morgan Stanley buys 3.13 crore equity shares in L&T Finance.

Suven will initially acquire a 67.5% equity stake of Sapala subject to customary working capital and net debt adjustments, the remaining stake a few months after FY2026-27, as per the terms of the definitive agreements, the company told stock exchanges.

Conference Call

Investor Presentation

Disclosure under Regulation 30 of the SEBI LODR regarding Acquisition

Pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that the management of the Company would be participating in various analyst/Institutional Investor meetings:

Transcript of the earnings conference call for the quarter and year ended March 31, 2024 conducted on May 30, 2024

Pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that the management of the Company would be participating in the Ambit - Titans of Tomorrow Conference on Friday, June 07, 2024Note: The schedule of the aforesaid meetings is subject to change. The change may happen due to exigencies on the part of Analyst / Institutional Investor / Company.No unpublished price-sensitive information will be shared during this interaction.

Newspaper advertisiment regarding to Financial Results of the Company

Audio recording of the earnings conference call for the quarter and year ended March 31, 2024

Outcome of the Board Meeting

Outcome of the Board Meeting

Outcome of the Board Meeting

Further to our letter dated May 21st , 2024, this is to inform you that the conference call for investors scheduled on Thursday, May 30, 2024 at 07:00 P.M IST to discuss the Audited Financial Results for the Q4 & FY24, has been preponed and rescheduled on Thursday, May 30, 2024 at 06.00 P.M IST to discuss the Audited Financial Results for the Q4 & FY24, to be declared on May 30, 2024. The revised invitation for conducting the conference call for investors is enclosed.

Pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that the management of the Company would be participating in the B&K - Trinity India Conference on Friday, 31st May 2024Note: The schedule of the aforesaid meetings is subject to change. The change may happen due to exigencies on the part of Analyst / Institutional Investor / Company.No unpublished price-sensitive information will be shared during this interaction.

Submission of Annual Secretarial Compliance Report for the F.Y. ended 31st March 2024

Further to our letter dated May 20th, 2024, this is to inform you that the conference call for investors scheduled on Monday, May 27, 2024 at 07:00 P.M IST to discuss the Audited Financial Results for the Q4 & FY24, has been postponed and rescheduled on Thursday, May 30, 2024 at 07.00 P.M IST to discuss the Audited Financial Results for the Q4 & FY24, to be declared on May 30, 2024. The revised invitation for conducting the conference call for investors is enclosed.

The Board Meeting to be held on 27/05/2024 has been revised to 30/05/2024 Further to our letter dated May 20th, 2024, this is to inform you that the meeting of the Board of Directors of the Company scheduled to be held on May 27, 2024, at the Corporate Office, 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIIC, Raidurg, Hyderabad, Telangana - 500081 of the Company, inter alia, to consider and approve the Audited Standalone and Consolidated financial results of the Company for the fourth quarter and financial year ended March 31, 2024 has been postponed and rescheduled to Thursday May 30th 2024.We would also like to inform that the Earnings Conference Call, which was scheduled on Monday 27th May 2024, at 7.00 p.m. (IST), to discuss on the Company's Audited Financial Results, has also been postponed accordingly. The revised Earnings Conference Call details will be notified through separate communication.

With reference to above subject, please find enclosed herewith an invitation for conducting the conference call for investors on Monday, May 27, 2024 at 07:00 P.M IST to discuss the Audited Financial Results for the Q4 & FY24, to be declared on May 27, 2024.

Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2024 ,inter alia, to consider and approve With reference to above subject, pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that a Meeting of the Board of Directors of the Company will be held on Monday, the 27th May, 2024 at 05:30 p.m. IST at the Corporate Office, 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIIC, Raidurg, Hyderabad, Telangana - 500081 of the Company, to consider, inter alia, and approve the following matter(s): To consider and approve the Audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the fourth quarter and year ended March 31, 2024 and other matters.Please further note that TRADING WINDOW for dealing in the securities of the company is already closed from 01st April, 2024 as per PIT Code of the Company. Trading window will be opened from 30th May, 2024.You are requested to take this notice on your record.

Apollo 24/7 is part of Apollo HealthCo, a subsidiary of Apollo Hospitals. HealthCo also houses the pharmacy distribution business and a 25.5% interest in Apollo Pharmacy. It accounts for about 40% of Apollo Hospitals’ revenue.

Apollo 24/7 is part of Apollo HealthCo, a subsidiary of Apollo Hospitals. HealthCo also houses the pharmacy distribution business and a 25.5% interest in Apollo Pharmacy. It accounts for about 40% of Apollo Hospitals’ revenue.

For the next couple of weeks, what will dominate the narrative on the street would be the action and expectation from the US Fed and Iran’s attack on Israel and whether it escalates further or not. At a time when events where no one has any control are hitting the street, two things are most important, first, don't react in panic. Now panic is not only about selling because the news is negative, but also about buying just because stock prices have fallen from its recent high. It is time to remember that there is not even a single year in the last 25 years, when there has not been an issue which made it appear that the world is going to crumble. But the fact is good businesses have still grown, valuations have still risen and broader markets have moved higher. So, these geopolitical tensions are part of life only if one focuses on what one is investing into and puts more checks and balances so that one is able to bring in the element of margins of safety.

Certificate under regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the quarter ended 31st March 2024

Compliance Certificate under regulation 7(3) of SEBI (LODR) 2015 for the year ended 31st March 2024.

Submission of compliance certificate for the year ended 31st March 2024 issued by the Practicing Company Secretary.